Fc Receptors

Part I : Old and new FcRs Hiromi Kubagawa, Yoshiki Kubagawa, Dewitt Jones, Tahseen H. Nasti, Mark Walter, and Kazuhito Honjo The Old but New IgM Fc Receptor (FcmuR) F.J. Li, W.J. Won, E.J. Becker Jr., J.L. Easlick, E. Tabengwa, R. Li, M. Shakhmatov, P.D. Burrows, and R.S. Davis Emerging Roles for FCRL Family Members in Lymphocyte Biology and Disease Leo C. James Intracellular antibody immunity and the cytosolic Fc receptor TRIM21 Part II: FcR signaling Anna Niarakis, Yacine Bounab, Luca Grieco, Roman Roncagalli, Jerome Garin, Bernard Malissen, Marc Daeron, Denis Thieffry Computational modeling of the main signaling pathways involved in mast cell activation Tarik Attout, Andres Floto and Pierre Launay Calcium channels in FcR signaling Marcel Kuhny, Carolin N. Zorn, and Michael Huber Regulation of FcepsilonRI signaling by lipid phosphatases Part III: FcR biology Marc Daeron Fc Receptors as Adaptive Immunoreceptors Jerrard M Hayes, Eoin FJ Cosgrave, Weston B Struwe, Mark Wormald, Gavin P. Davey, Roy Jefferis, Pauline M Rudd Glycosylation and Fc Receptors Birgitta Heyman Antibodies as natural adjuvants Sanae Ben Mkaddem, Ivy Christou, Elisabetta Rossato, Laureline Berthelot, Agnes Lehuen and Renato C. Monteiro IgA, IgA receptors and their anti-inflammatory properties Stylianos Bournazos, David J. DiLillo and Jeffrey V. Ravetch Humanized mice to study FcgammaR function Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober and E. Sally Ward FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Part IV: FcRs and disease Xinrui Li, Andrew W Gibson and Robert P Kimberly Human FcR polymorphism and disease. Hanane el Bannoudi, Andreea Ioan-Facsinay and Rene E. M. Toes Bridging auto-antibodies and arthritis; the role of Fc Receptors P. Mark Hogarth, Jessica C. Anania, Bruce D. Wines The FcgammaR of humans and non-human primates and their interaction with IgG: Implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies Part V: FcRs and therapeutic antibodies Ann L White, Stephen A Beers and Mark S. Cragg FcgRIIB as a key determinant of agonistic antibody efficacy Jantine E. Bakema and Marjolein van Egmond Fc receptor dependent mechanisms of monoclonal antibody therapy of cancer; professionals at work Sybille Bohm, Daniela Kao and Falk Nimmerjahn Sweet and Sour: The role of glycosylation for the anti-inflammatory activity of immunoglobulin G